Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

armeeapotheke - immunoglobulinum cavalli bitis arietans, immunoglobulinum cavalli bitis gabonica, immunoglobulinum cavalli hemachatus haemachatus, immunoglobulinum cavalli dendroaspis angusticeps, immunoglobulinum cavalli dendroaspis jamesoni, immunoglobulinum cavalli dendroaspis polylepis, immunoglobulinum cavalli naja nivea, immunoglobulinum cavalli naja melanoleuca, immunoglobulinum cavalli naja annulifera, immunoglobulinum cavalli naja mossambica - saimr polivalente serpente antiveleno - lösung: immunoglobulinum equis bitis arietans, immunoglobulinum equis bitis gabonica, immunoglobulinum equis hemachatus haemachatus, immunoglobulinum equis dendroaspis angusticeps, immunoglobulinum equis dendroaspis jamesoni, immunoglobulinum equis dendroaspis polylepis, immunoglobulinum equis naja nivea, immunoglobulinum equis naja melanoleuca, immunoglobulinum equis naja annulifera, immunoglobulinum equis naja mossambica, für alle globuline: dosierung gemäss fi, natrii chloridum, conserv.: metacresolum ≤ 0.35 % m/v, aqua ad iniectabile, q.s. ad solutionem. - antiveleno - antivenine

Italia - italiano - Ministero della Salute

etro -

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.   - paliperidone palmitato - schizofrenia - psicolettici - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - candida albicans aquos d5 - gocce per uso orale - candida albicans aquos d5 dilutio. - gemäss homöopathischem arzneimittelbild bei ekzemen und mykosen - farmaci omeopatici

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - candida albicans aquos d5 - injektionslösung (i.m., s.c., i.c.) - candida albicans aquos d5 dilutio, natrii chloridum, per la soluzione. - gemäss homöopathischem arzneimittelbild bei ekzemen und mykosen. - farmaci omeopatici

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - candida albicans d4 - capsule - candida albicans, d4 trituratio 330 mg, excipiens pro capsula. - gemäss homöopathischem arzneimittelbild bei ekzemen und mykosen - farmaci omeopatici

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - candida albicans aquos d3 - salve - candida albicans aquos d3 dilutio 100 mg, alcoli nostro nuovo e vaselinum album e alcol cetylicus e stearylicus, triglycerida media, glyceroli monostearas 40-55, acido lacticum, magnesio sulfas heptahydricus, propylenglycolum, acqua q.s. il profumo per 1 g. - gemäss homöopathischem arzneimittelbild bei ekzemen und mykosen - farmaci omeopatici

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - candida albicans d3 - zäpfchen - candida albicans d3 trituratio 200 mg, excipiens pro suppositorio. - gemäß homöopathischem arzneimittelbild bei ekzemen und mykosen - farmaci omeopatici

Unione Europea - italiano - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenti antineoplastici - azacitidina accord è indicato per il trattamento di pazienti adulti che non sono eleggibili per il trapianto di cellule staminali ematopoietiche (hsct) con:- intermedio-2 e ad alto rischio di sindromi mielodisplastiche (mds) secondo l'international prognostic scoring system (ipss),- leucemia mielomonocitica cronica (cmml) con 10-29 % di midollo esplosioni senza mieloproliferative disturbo,- leucemia mieloide acuta (aml) con 20-30 % di blasti e multi-lineage displasia, secondo l'organizzazione mondiale della sanità (oms) classificazione,- aml con >30% midollo di blasti secondo la classificazione who.